Revenue
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Johnson & Johnson (JNJ)
Price$276.32Cached quote
Net income
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $94.19B | $88.82B | $85.16B | $79.99B | $78.74B | $82.58B | $82.06B | $81.58B | $76.45B | $71.89B | $70.07B | $74.33B | $71.31B | $67.22B | $65.03B | $61.59B | $61.90B | $63.75B | $61.09B |
| Gross profit | $63.94B | $61.35B | $58.61B | $55.39B | $55.34B | $54.16B | $54.50B | $54.49B | $51.01B | $50.10B | $48.54B | $51.59B | $48.97B | $45.57B | $44.67B | $42.80B | $43.45B | $45.24B | $43.34B |
| Gross margin | 67.88% | 69.07% | 68.82% | 69.25% | 70.28% | 65.58% | 66.42% | 66.79% | 66.72% | 69.69% | 69.27% | 69.40% | 68.67% | 67.78% | 68.69% | 69.49% | 70.20% | 70.96% | 70.95% |
| Research & development | $14.66B | $17.23B | $15.09B | $14.13B | $14.28B | $12.16B | $11.36B | $10.78B | $10.59B | $9.14B | $9.05B | $8.49B | $8.18B | $7.67B | $7.55B | $6.84B | $6.99B | $7.58B | $7.68B |
| Operating expenses | $38.34B | $40.10B | $36.60B | $34.38B | N/A | N/A | N/A | N/A | N/A | N/A | N/A | $30.00B | $32.56B | $30.61B | $30.91B | $25.09B | $26.87B | N/A | N/A |
| Operating income | $25.60B | $21.25B | $22.01B | $21.01B | N/A | N/A | N/A | N/A | N/A | N/A | N/A | $21.59B | $16.41B | $14.96B | $13.77B | $17.70B | $16.58B | N/A | N/A |
| Operating margin | 27.17% | 23.92% | 25.84% | 26.27% | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 29.05% | 23.01% | 22.25% | 21.17% | 28.74% | 26.79% | N/A | N/A |
| EBITDA | $41.05B | $24.78B | $23.32B | $26.61B | N/A | N/A | N/A | N/A | N/A | N/A | N/A | $25.48B | $20.52B | $18.62B | $16.92B | $20.64B | $19.36B | N/A | N/A |
| EBITDA margin | 43.59% | 27.90% | 27.38% | 33.26% | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 34.29% | 28.77% | 27.70% | 26.02% | 33.51% | 31.27% | N/A | N/A |
| Net income | $26.80B | $14.07B | $35.15B | $17.94B | $20.88B | $14.71B | $15.12B | $15.30B | $1.30B | $16.54B | $15.41B | $16.32B | $13.83B | $10.85B | $9.67B | $13.33B | $12.27B | $12.95B | $10.58B |
| Net profit margin | 28.46% | 15.84% | 41.28% | 22.43% | 26.52% | 17.82% | 18.42% | 18.75% | 1.70% | 23.01% | 21.99% | 21.96% | 19.40% | 16.14% | 14.87% | 21.65% | 19.82% | 20.31% | 17.31% |
| Basic EPSper basic share | $11.13 | $5.84 | $13.88 | $6.83 | $7.93 | $5.59 | $5.72 | $5.70 | $0.48 | $6.04 | $5.56 | $5.80 | $4.92 | $3.94 | $3.54 | $4.85 | $4.45 | $4.62 | $3.67 |
| Diluted EPSper diluted share | $11.03 | $5.79 | $13.72 | $6.73 | $7.81 | $5.51 | $5.63 | $5.61 | $0.47 | $5.93 | $5.48 | $5.70 | $4.81 | $3.86 | $3.49 | $4.78 | $4.40 | $4.57 | $3.63 |
Owners
Reported shareholders
≈8.80%of listed shares
BlackRock, Inc.212.1M shares · Jun 30, 2026
View holders
| Holder | % owned |
|---|---|
BlackRock, Inc. | ≈8.80%212.1M shares |
VANGUARD CAPITAL MANAGEMENT LLC | ≈6.52%157.23M shares |
STATE STREET CORP | ≈5.55%133.78M shares |
VANGUARD PORTFOLIO MANAGEMENT LLC | ≈2.67%64.37M shares |
GEODE CAPITAL MANAGEMENT, LLC | ≈2.45%59.09M shares |
JPMORGAN CHASE & CO | ≈2.42%58.3M shares |
MORGAN STANLEY | ≈1.86%44.81M shares |
NORGES BANK | ≈1.32%31.83M shares |
STATE FARM MUTUAL AUTOMOBILE INSURANCE CO | ≈1.31%31.59M shares |
NORTHERN TRUST CORP | ≈1.19%28.79M shares |
BANK OF AMERICA CORP /DE/ | ≈0.97%23.44M shares |
PRICE T ROWE ASSOCIATES INC /MD/ | ≈0.95%23M shares |
FMR LLC | ≈0.94%22.6M shares |
WELLINGTON MANAGEMENT GROUP LLP | ≈0.94%22.59M shares |
Bank of New York Mellon Corp | ≈0.90%21.68M shares |
GOLDMAN SACHS GROUP INC | ≈0.82%19.72M shares |
Legal & General Group Plc | ≈0.80%19.29M shares |
CHARLES SCHWAB INVESTMENT MANAGEMENT INC | ≈0.79%19.13M shares |
UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | ≈0.76%18.42M shares |
WELLS FARGO & COMPANY/MN | ≈0.72%17.37M shares |
Percentages use 2.41B shares of this listed class outstanding on Jul 17, 2026. ≈ compares the latest reported holding with a share total from a different date; it is not a confirmed current stake.
Gray completes the 100% scale. Reported positions may overlap; holders have different reporting dates.
Source: SEC Form 13F ↗Updated Oct 29, 2026 · Quarterly data
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Sep 2, 2026Form 4 | Schmid TimothyEVP, WW Chair, MedTech | SellCommon Stock | 22.5K | $274.74 | $6.19M | 25.4K |
| Sep 2, 2026Form 4 | Schmid TimothyEVP, WW Chair, MedTech | SellCommon Stock | 11.1K | $274.74 | $3.04M | 25.4K |
| Aug 17, 2026Form 4 | Taubert Jennifer LEVP, WWC. Innovative Medicine | SellCommon Stock | 15.0K | $263.36 | $3.95M | 194.5K |
| Aug 13, 2026Form 4 | Duato JoaquinCEO and Chairman of the Board | SellCommon Stock | 102.3K | $261.00 | $26.70M | 276.0K |
| Aug 13, 2026Form 4 | Duato JoaquinCEO and Chairman of the Board | SellCommon Stock | 21.0K | $262.00 | $5.50M | 378.3K |
Community posts
J&J reports surgery-comparator benefit for Erleada in prostate cancer
Johnson & Johnson ($JNJ) reported new PROTEUS substudy results comparing Erleada plus hormone therapy before and after prostate surgery with surgery alone. Among 408 patients with high-risk localized or locally advanced disease, the regimen ...
J&J reports early prostate-cancer responses for experimental oral drug
Johnson & Johnson ($JNJ) disclosed early results for oral JNJ-6143 in heavily pretreated advanced prostate cancer. Among 31 evaluable patients receiving 50 milligrams, 77% achieved at least a 50% PSA decline. Confirmed tumor responses occur ...
Carvykti follow-up finds half of a small cohort progression-free at five years
Johnson & Johnson ($JNJ) and Legend Biotech ($LEGN) reported five-year follow-up from 20 patients in the Phase 2 CARTITUDE-2 Cohort A study of Carvykti. Ten remained alive without disease progression or further anti-myeloma treatment after ...
Johnson & Johnson says Tremfya meets axial psoriatic-arthritis trial goals
Johnson & Johnson ($JNJ) said Tremfya met the primary and key secondary endpoints in STAR, a randomized, double-blind Phase 4 study in patients with axial manifestations of psoriatic arthritis. The company reported improvement over placebo ...
Apollo reportedly nears $20 billion talks for J&J orthopedics business
Apollo ($APO) is in talks to acquire Johnson & Johnson’s ($JNJ) DePuy Synthes orthopedics business in a transaction that could be worth around $20 billion, Reuters reported, citing Bloomberg. The unit generated approximately $9.3 billion in ...
